These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 4718046)

  • 81. Sickle-cell disease and the properdin system.
    Rosen FS
    N Engl J Med; 1973 Apr; 288(16):845-6. PubMed ID: 4144345
    [No Abstract]   [Full Text] [Related]  

  • 82. An abnormality of the alternate pathway of complement activation in sickle-cell disease.
    Johnston RB; Newman SL; Struth AG
    N Engl J Med; 1973 Apr; 288(16):803-8. PubMed ID: 4144343
    [No Abstract]   [Full Text] [Related]  

  • 83. Introduction: complement diseases in man.
    Miller ME
    Birth Defects Orig Artic Ser; 1975; 11(1):299-300. PubMed ID: 1148384
    [No Abstract]   [Full Text] [Related]  

  • 84. Increased susceptibility to infection in sickle cell disease: defects of opsonization and of splenic function.
    Johnston RB; Newman SL; Struth AG
    Birth Defects Orig Artic Ser; 1975; 11(1):322-7. PubMed ID: 238677
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Opsonins: their function, identity, and clinical significance.
    Winkelstein JA
    J Pediatr; 1973 May; 82(5):747-53. PubMed ID: 4144636
    [No Abstract]   [Full Text] [Related]  

  • 86. Molecular basis for functional disorders of phagocytes.
    Baehner RL
    J Pediatr; 1974 Mar; 84(3):317-27. PubMed ID: 4590714
    [No Abstract]   [Full Text] [Related]  

  • 87. Phagocytosis: The normal process and its clinically significant abnormalities.
    Winkelstein JA; Drachman RH
    Pediatr Clin North Am; 1974 Aug; 21(3):551-69. PubMed ID: 4606904
    [No Abstract]   [Full Text] [Related]  

  • 88. [Immunologic tests: Opsonin].
    Suzuki A; Ishii S
    Nihon Rinsho; 2005 Jul; 63 Suppl 7():101-3. PubMed ID: 16111200
    [No Abstract]   [Full Text] [Related]  

  • 89. [Clinical-immunologic significance of complement].
    Stelzner A; Tanner E; Stein G; Umland T
    Dtsch Gesundheitsw; 1971 Apr; 26(18):837-43. PubMed ID: 4931865
    [No Abstract]   [Full Text] [Related]  

  • 90. Immunodeficiency states and associated rheumatic manifestations.
    Espinoza LR; Gutierrez S; Berman A
    Curr Opin Rheumatol; 1995 Jan; 7(1):65-9. PubMed ID: 7718426
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Methods of studying nonspecific body resistance used in hygiene].
    Golikov VIa; Taranenko LA
    Gig Sanit; 1982 Jul; (7):52-5. PubMed ID: 6751943
    [No Abstract]   [Full Text] [Related]  

  • 92. New uses for IVIgG immunoglobulin therapies.
    Wallington T
    Vox Sang; 2004 Jul; 87 Suppl 2():155-7. PubMed ID: 15209904
    [No Abstract]   [Full Text] [Related]  

  • 93. [Factor I deficiency].
    Fujita T
    Ryoikibetsu Shokogun Shirizu; 2000; (32):250-2. PubMed ID: 11212709
    [No Abstract]   [Full Text] [Related]  

  • 94. Immunodeficiency in sickle-cell anemia.
    Ringelhann B
    N Engl J Med; 1973 Aug; 289(6):326-7. PubMed ID: 4718046
    [No Abstract]   [Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 5.